A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

  • Authors:
    • Bengt Sorbe
    • Marianne Graflund
    • Lisa Nygren
    • György Horvath
    • Marie Swahn
    • Karin Boman
    • René Bangshöj
    • Margareta Lood
    • Henric Malmström
  • View Affiliations

  • Published online on: December 7, 2011     https://doi.org/10.3892/ijo.2011.1286
  • Pages: 773-781
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to assess the response rate, toxicity, progression-free survival (PFS) and overall survival (OS) in a series of advanced stage ovarian carcinoma patients treated with a first-line weekly docetaxel and three weekly carboplatin regimens. All eligible patients were treated with intravenous docetaxel (30 mg/m2) on Days 1, 8 and 15, and carboplatin (area under the curve, 5) on Day 1; Q21 days for at least 6 cycles. Neurological tests, questionnaires, and the EORTC QLQ-C30 and OV28 were used for quality-of-life assessments. One hundred and six patients received at least one cycle of primary chemotherapy (median 6.0; range, 1-9) and they were evaluable for toxicity assessment. Eighty-five patients had evaluable disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% CI 70.1-87.5%) and the biochemical response was 92.8% (95% CI 87.2-98.4%). The median PFS was 12.0 months and the median OS was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3-4 sensory neuropathy. Epiphora, nail changes and fatigue were frequently recorded non-hematological side effects. The tolerable hematological toxicity (no need for colony-stimulating factors) and the low rate of severe neurotoxicity (only grade 1-2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients.

Related Articles

Journal Cover

March 2012
Volume 40 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M and Malmström H: A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation. Int J Oncol 40: 773-781, 2012
APA
Sorbe, B., Graflund, M., Nygren, L., Horvath, G., Swahn, M., Boman, K. ... Malmström, H. (2012). A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation. International Journal of Oncology, 40, 773-781. https://doi.org/10.3892/ijo.2011.1286
MLA
Sorbe, B., Graflund, M., Nygren, L., Horvath, G., Swahn, M., Boman, K., Bangshöj, R., Lood, M., Malmström, H."A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation". International Journal of Oncology 40.3 (2012): 773-781.
Chicago
Sorbe, B., Graflund, M., Nygren, L., Horvath, G., Swahn, M., Boman, K., Bangshöj, R., Lood, M., Malmström, H."A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation". International Journal of Oncology 40, no. 3 (2012): 773-781. https://doi.org/10.3892/ijo.2011.1286